Ouro Medicines

Ouro Medicines is a clinical-stage biotechnology company that develops T cell engager immunotherapies for treatment of chronic immune-mediated diseases, particularly B cell-mediated autoimmune conditions. The company's lead therapeutic candidate OM336, also known as gamgertamig, is a BCMAxCD3 T cell engager designed to induce rapid and deep B cell depletion for treatment of antibody-mediated orphan diseases including autoimmune hemolytic anemia and immune thrombocytopenia. Ouro's approach combines T cell engager technology with protein engineering expertise to develop next-generation therapeutics targeting B cell biology for autoimmune diseases. The company was founded through a partnership between Monograph Capital and GSK with a Series A funding round of $120 million. Initial clinical development activities are underway with ongoing Phase 1/2 clinical studies evaluating the lead program. The company was founded in 2025 and is headquartered in San Francisco, California, United States.